The Journal of Physiological Sciences

, Volume 67, Issue 3, pp 353–360 | Cite as

Regulation of osmolality for cancer treatment

Mini-review

Abstract

Disseminated metastasis is associated with a poor prognosis, and its management in the peritoneal or pleural cavity is crucial in the treatment of cancer. Recent studies show that ion and water transporters play important roles in fundamental cellular functions, including the regulation of cell volume that would be involved in the cancer process. Here, we review the evidence for hypotonic treatments of cancer and evaluate the potential of the cellular physiological approach in clinical management. The regulation of extracellular osmolality is a promising method, with several studies demonstrating the cytocidal effects of hypotonic solution on cancer cells. Peritoneal lavage with distilled water (DW) during surgery is reported to improve the survival rate of patients with spontaneously ruptured hepatocellular carcinoma. The in vitro studies included in this review also indicate the cytocidal effects of hypotonic shock on esophageal, gastric, colonic, pancreatic, and liver cancer cells with several unique methods and apparatuses, such as a differential interference contrast microscope connected to a digital video camera, a high-resolution flow cytometer and re-incubation analysis. The in vivo studies demonstrate the safeness of a peritoneal injection of DW into mice and indicate that the development of dissemination nodules can be prevented by the pre-incubation of cancer cells with DW or the peritoneal injection of DW. We also demonstrate that the blockade of Cl channels/transporters enhances the cytocidal effects of hypotonic shock by inhibiting regulatory volume decrease in various cancer cells. A deeper understanding of molecular mechanisms may lead to the discovery of these cellular physiological approaches as a novel therapeutic strategy for disseminated metastasis.

Keywords

Disseminated metastasis Cancer Hypotonic treatment Regulatory volume decrease Cl channel 

Notes

Acknowledgements

The authors would like to thank Dr. Michihiro Kudou for technical assistance with the experiments.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rajdev L (2010) Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 11:14–23CrossRefPubMedGoogle Scholar
  2. 2.
    Lim L, Michael M, Mann GB, Leong T (2005) Adjuvant therapy in gastric cancer. J Clin Oncol 23:6220–6232CrossRefPubMedGoogle Scholar
  3. 3.
    Van-den-Broeck A, Sergeant G, Ectors N, Van-Steenbergen W, Aerts R, Topal B (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600–604CrossRefPubMedGoogle Scholar
  4. 4.
    Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725CrossRefPubMedGoogle Scholar
  5. 5.
    Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ (2009) Gastric cancer. Lancet 374:477–490CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H, Kitayama J (2012) Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci 103:1304–1310CrossRefPubMedGoogle Scholar
  7. 7.
    Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K (2014) Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer 45:307–311CrossRefPubMedGoogle Scholar
  8. 8.
    Fraser SP, Pardo LA (2008) Ion channels: functional expression and therapeutic potential in cancer. Colloquium on ion channels and cancer. EMBO Rep 9:512–515CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pedersen SF, Stock C (2013) Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res 73:1658–1661CrossRefPubMedGoogle Scholar
  10. 10.
    Schönherr R (2005) Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 205:175–184CrossRefPubMedGoogle Scholar
  11. 11.
    Miyazaki H, Marunaka Y (2015) The molecular mechanism of intracellular Cl function in gastric cancer invasion and metastasis by regulating expression of cell adhesion molecules. J Physiol Sci 65[Suppl 1]:72Google Scholar
  12. 12.
    Takada T, Takata K, Ashihara E (2016) Inhibition of monocarboxylate transporter 1 suppresses the proliferation of glioblastoma stem cells. J Physiol Sci 66:387–396CrossRefPubMedGoogle Scholar
  13. 13.
    Marunaka Y (2016) Cl and H+ as mediators of biofunction and biodysfunction in health and disease. J Physiol Sci 66[Suppl 1]:4Google Scholar
  14. 14.
    Miyazaki H, Ue T, Tanaka S, Nakayama Y, Marunaka Y (2016) The molecular mechanism of intracellular Cl in cancer progression by regulating Src kinase signal cascades. J Physiol Sci 66[Suppl 1]:159Google Scholar
  15. 15.
    Park KG, Chetty U, Scott W, Miller W (1991) The activity of locally applied cytotoxics to breast cancer cells in vitro. Ann R Coll Surg Engl 73:96–99PubMedPubMedCentralGoogle Scholar
  16. 16.
    Huguet EL, Keeling NJ (2004) Distilled water peritoneal lavage after colorectal cancer surgery. Dis Colon Rectum 47:2114–2119CrossRefPubMedGoogle Scholar
  17. 17.
    Zhou SJ, Zhang EL, Liang BY, Zhang ZY, Chen XP, Huang ZY (2015) Distilled water lavage during surgery improves long-term outcomes of patients with ruptured hepatocellular carcinoma. J Gastrointest Surg 19:1262–1270CrossRefPubMedGoogle Scholar
  18. 18.
    Fechner G, Pocha K, Schmidt D, Muller SC (2006) Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. Int J Clin Pract 60:1178–1180CrossRefPubMedGoogle Scholar
  19. 19.
    Levin DR, Moskovitz B (1986) Distilled water versus chemotherapeutic agents for transitional bladder carcinoma. Eur Urol 12:418–421PubMedGoogle Scholar
  20. 20.
    Ichinose Y, Hara N, Ohta M, Asoh H, Yano T, Maeda K, Yagawa K (1993) Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results. J Thorac Cardiovasc Surg 10:1041–1046Google Scholar
  21. 21.
    Mercill DB, Jones NR, Harbell JW (1985) Human tumor cell destruction by distilled water. An in vitro evaluation. Cancer 55:2779–2782CrossRefPubMedGoogle Scholar
  22. 22.
    Kosuga T, Shiozaki A, Ichikawa D, Fujiwara H, Komatsu S, Iitaka D, Tsujiura M, Morimura R, Takeshita H, Nagata H, Okamoto K, Nakahari T, Marunaka Y, Otsuji E (2011) Pleural lavage with distilled water during surgery for esophageal squamous cell carcinoma. Oncol Rep 26:577–586PubMedGoogle Scholar
  23. 23.
    Iitaka D, Shiozaki A, Ichikawa D, Kosuga T, Komatsu S, Okamoto K, Fujiwara H, Ishii H, Nakahari T, Marunaka Y, Otsuji E (2012) Blockade of chloride ion transport enhances the cytocidal effect of hypotonic solution in gastric cancer cells. J Surg Res 176:524–534CrossRefPubMedGoogle Scholar
  24. 24.
    Nako Y, Shiozaki A, Ichikawa D, Komatsu S, Konishi H, Iitaka D, Ishii H, Ikoma H, Kubota T, Fujiwara H, Okamoto K, Ochiai T, Nakahari T, Marunaka Y, Otsuji E (2012) Enhancement of the cytocidal effects of hypotonic solution using a chloride channel blocker in pancreatic cancer cells. Pancreatology 12:440–448CrossRefPubMedGoogle Scholar
  25. 25.
    Takemoto K, Shiozaki A, Ichikawa D, Komatsu S, Konishi H, Nako Y, Murayama Y, Kuriu Y, Nakanishi M, Fujiwara H, Okamoto K, Sakakura C, Nakahari T, Marunaka Y, Otuji E (2015) Evaluation of the efficacy of peritoneal lavage with distilled water in colorectal cancer surgery: in vitro and in vivo study. J Gastroenterol 50:287–297CrossRefPubMedGoogle Scholar
  26. 26.
    Kudou M, Shiozaki A, Kosuga T, Ichikawa D, Konishi H, Morimura R, Komatsu S, Ikoma H, Fujiwara H, Okamoto K, Hosogi S, Nakahari T, Marunaka Y, Otsuji E (2016) Inhibition of regulatory volume decrease enhances the cytocidal effect of hypotonic shock in hepatocellular carcinoma. J Cancer 7:1524–1533CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Caplanusi A, Kim KJ, Lariviere E, Van Driessche W, Jans D (2006) Swelling-activated K+ efflux and regulatory volume decrease efficiency in human bronchial epithelial cells. J Membr Biol 214:33–41CrossRefPubMedGoogle Scholar
  28. 28.
    Miyazaki H, Shiozaki A, Niisato N, Marunaka Y (2007) Physiological significance of hypotonicity-induced regulatory volume decrease: reduction in intracellular Cl concentration acting as an intracellular signaling. Am J Physiol Renal Physiol 292:F1411–1417CrossRefPubMedGoogle Scholar
  29. 29.
    Taoka R, Williams SB, Ho PL, Kamat AM (2015) In-vitro cytocidal effect of water on bladder cancer cells: the potential role for intraperitoneal lavage during radical cystectomy. Can Urol Assoc J 9:E109–113CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ito F, Camoriano M, Seshadri M, Evans SS, Kane JM 3rd, Skitzki JJ (2011) Water: a simple solution for tumor spillage. Ann Surg Oncol 18:2357–2363CrossRefPubMedGoogle Scholar
  31. 31.
    Shiozaki A, Ichikawa D, Takemoto K, Nako Y, Nakashima S, Shimizu H, Kitagawa M, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K, Marunaka Y, Otsuji E (2014) Efficacy of a hypotonic treatment for peritoneal dissemination from gastric cancer cells: an in vivo evaluation. Biomed Res Int 2014:707089PubMedPubMedCentralGoogle Scholar
  32. 32.
    Morris PC, Scholten V (1996) Osmotic lysis of tumor spill in ovarian cancer: a murine model. Am J Obstet Gynecol 175:1489–1492CrossRefPubMedGoogle Scholar
  33. 33.
    Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N (1996) Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 73:1166–1170CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Katano K, Tsujitani S, Oka S, Saito H, Gomyo Y, Kondo A, Ikeguchi M, Maeta M, Kaibara N (2000) Pharmacokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and the pleural cavities in experimental model. Anticancer Res 20:1603–1607PubMedGoogle Scholar
  35. 35.
    Whiteside OJ, Tytherleigh MG, Thrush S, Farouk R, Galland RB (2005) Intra-operative peritoneal lavage—who does it and why? Ann R Coll Surg Engl 87:255–258CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lin CH, Hsieh HF, Yu JC, Chen TW, Yu CY, Hsieh CB (2006) Peritoneal lavage with distilled water during liver resection in patients with spontaneously ruptured hepatocellular carcinomas. J Surg Oncol 94:255–256CrossRefPubMedGoogle Scholar
  37. 37.
    Chang YM, Hsu KF, Yu JC, Chan DC, Chen CJ, Chen TW, Hsieh CB, Hsieh HF (2013) Distilled water peritoneal lavage in patients with rupture hepatocellular carcinoma. Hepatogastroenterology 60:140–143PubMedGoogle Scholar
  38. 38.
    Ichinose Y, Yano T, Asoh H, Yokoyama H, Fukuyama Y, Miyagi J, Kuninaka S, Terazaki Y (1997) Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. J Surg Oncol 66:196–200CrossRefPubMedGoogle Scholar
  39. 39.
    Ichinose Y, Tsuchiya R, Koike T, Yasumitsu T, Nakamura K, Tada H, Yoshimura H, Mitsudomi T, Nakagawa K, Yokoi K, Kato H (2002) A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg 123:695–699CrossRefPubMedGoogle Scholar
  40. 40.
    Tsujitani S, Fukuda K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N (2002) The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery 131:S98–S104CrossRefPubMedGoogle Scholar
  41. 41.
    Katano K, Tsujitani S, Maeta M, Fukuda K, Oka S, Hisamitsu K, Ikeguchi M, Kaibara N (2001) Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer. Oncol Rep 8:605–609PubMedGoogle Scholar
  42. 42.
    Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y, Semba H, Ichinose Y, Thoracic Oncology Group (2006) Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 95:717–721CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Physiological Society of Japan and Springer Japan 2017

Authors and Affiliations

  1. 1.Division of Digestive Surgery, Department of SurgeryKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of Molecular Cell Physiology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
  3. 3.Department of Bio-Ionomics, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
  4. 4.Japan Institute for Food Education and HealthSt. Agnes’ UniversityKyotoJapan

Personalised recommendations